Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously Dr. Abrahams was executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
CEO, M2Gen; Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. William (Bill) S. Dalton is Founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
Vice President, Oncology Medical Sciences, Astellas Pharma Global Development
Dr. Eck is Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development including both early phase clinical studies and late stage drug development studies. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).
Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science (Pharmaceutical Sciences). He serves on the Scientific Advisory Board of the ACGT Foundation (which supports academic cancer research), and is a member of the Executive Committee of the Fairbanks Institute (an institution dedicated to developing data banks to enable personalized medicine). He also serves on the Advisory Board of the Keck Graduate School (Claremont, CA).
Retired, Abbot Molecular
D. Stafford O'Kelly, retired, was formerly President of Abbott Molecular. He served in this role from 2007-2012.
Mr. O'Kelly joined Abbott in 1984 and served in various management positions. These included Vice President, Latin America/Canada Operations; Division Vice President Finance, Abbott International, Division; Vice President and Controller, Ross Products Division (now Abbott Nutrition); and Vice President, Finance, TAP Pharmaceuticals, Inc.
Mr. O'Kelly serves on the boards of Youth Conservation Corps, Inc., and the Clara Abbott Foundation.
He has a bachelor's degree in engineering and MBA from Trinity College in Dublin, Ireland.
Chief Medical Officer & Senior Vice President of Oncology, Flatiron Health, Professor of Medicine, Duke University
Before joining Flatiron, Amy was Professor of Medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support personalized medicine and scientific discovery. Joining Flatiron was the obvious next step.
Amy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine. As an oncologist and palliative care physician, she sincerely believes in putting the patient in the center of the health care story and ensuring that the solutions we build have patient best interests at heart. She is also a mother of two and an avid traveler.
With over 375 publications, Amy is an internationally recognized expert in health services research, comparative effectiveness research, patient reported outcomes, clinical informatics and patient-centered care. She maintains her role at Duke 20 percent, and is an appointee to the Institute of Medicine’s National Cancer Policy Forum, Immediate Past President of the American Academy of Hospice & Palliative Medicine, Secretary of the Board of Directors for the Personalized Medicine Coalition, and leader within several federally-funded research networks. She serves on the Advisory Committee of the Turning the Tide Against Cancer policy initiative. She also serves on the Board of Directors for athenahealth.
Senior Vice President, Government Affairs, Endo Pharmaceuticals
Brian Munroe is the founder and the immediate Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of the PMC Public Policy Committee and on the Executive Committee of the PMC Board of Directors.
Brian is a twenty year veteran of health care public policy, advocacy, and communications. His areas of expertise are in FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently the Vice-President in charge of Washington office, the Public Policy group, State Government Relations and, the Political Action Committee at Endo. He also serves on Endo’s Executive Operations Committee.
Brian’s breadth in health care policy stretches across pharma/biotech, home health care, diagnostics, medical devices, clinical laboratories, and health care payors. His geographical responsibilities have included the fifty states, the Federal government and Congress, and for a short time the European Union and member countries.
Brian began his career in Washington, D.C. working for United States Senator Alan Cranston (D-CA).
Brian currently lives in the Washington, D.C. area with his wife Vicky and their four children.
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on health care strategy and policy issues related to science and medicine, a member of the Ethics and Systems Medicine Program at Georgetown University and Chairman of the board of directors of the Personalized Medicine Coalition. He is also VP Strategic Consulting at Fuld & Company focusing on strategic simulations in health care, Chief Scientific Advisor at Expertech focusing on strategic futuring for Air Force Medical Systems, and Chief Applications Officer for SciTech Strategies focusing on scientific competency and capacity development for academia and industry.
He is a former Director of External Relations for Personalized Healthcare and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he had responsibility for long-range external relations strategy and policy development. Prior to that role, he was involved in long-term strategy development for the AstraZeneca Discovery, Development, and US Commercial divisions, and created and ran strategic intelligence units at both AstraZeneca and SmithKIine Beecham Pharmaceuticals. He is a former President of SCIP (Society of Competitive Intelligence Professionals) and has received the SCIP Fellows Award and Lifetime Achievement Award in Intelligence from Frost and Sullivan.
Wayne is active on strategy and advisory boards of several organizations including the IOM, IBM Life Sciences, and Hewlett-Packard Life Sciences. He has presented at numerous forums on aspects of personalized health care, evidence-based medicine, new development paradigms, and strategy development. He holds a B.S. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston University, and received post-doctoral training in Cancer and Radiation Biology at the University of Rochester. Wayne lives in Malvern, Pa., is married with two college-age children, and enjoys teaching martial arts (Tang Soo Do), restoring antique/classic Fords, and aviation history.
Vice President, Translational Clinical Development, Pharmacodiagnostics, Bristol-Myers Squibb Company
Dr. Averbuch is currently Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA. In this role, Steve serves as the Executive Sponsor of the Translational R&D teams across the Full Development and Life Cycle Management pipeline while working to optimize knowledge sharing and biomarker tools across all of R&D to achieve stratified medicine development. Steve also leads the Pharmacodiagnostics Center of Excellence with its mission to drive strategy and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to BMS products.
Steve joined BMS in 2006. Previously he co-led the Oncology early strategy team and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs. He has made significant Global Clinical Research contributions to business development and he has participated in seven successful acquisitions.
Steve previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and he is a co-author on one patent. He is currently on the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations.
Retired, Luminex Corporation
Mr. Balthrop has been Chief Executive Officer and President of Luminex Corporation since May 2004. Since he joined Luminex, the company has increased revenue over six fold at a compound annual revenue growth of 25%. During this period R&D investment has grown even faster at 30% while corporate gross margins have increased from less than 45% to almost 70%. Luminex has been recognized as an innovation leader, having introduced a number of groundbreaking, first-of-their-kind products in infectious disease, genetic disease, personalized medicine and complex multiplexing instrument systems.
In recent years, Luminex has been awarded the prestigious Prix Galien Award, considered the industry equivalent to the Nobel Prize, for Best Medical Technology based on the company’s innovative products, as well as additional awards for design excellence. Luminex has also consistently been honored as one of the 25 fastest growing technology companies in America by Forbes, and as one of the 100 fastest growing companies across all industries by Fortune.
Before joining Luminex, Mr. Balthrop was President of Fisher Healthcare, a $1 billion integrated business. Prior to Fisher, Mr. Balthrop served in a number of leadership positions for 20 years around the globe with Abbott in diagnostics and vascular devices. His career experience has included R&D, worldwide commercial operations, manufacturing, international general management and intellectual property management.
Mr. Balthrop was educated at Northwestern University's Kellogg School of Management, Princeton University and Spring Hill College. He holds an MBA and a BS in Biology.
Chief Medical Officer (Consulting), Genetic Sciences Division of Thermo Fisher Scientific
Board-certified internist and clinical geneticist, Dr. Paul R. Billings serves as Chief Medical Officer (Consulting) for the Genetic Sciences Division of Thermo Fisher Scientific, a unique position aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. Dr. Billings has extensive expertise and health care experience in the areas of genomics and molecular medicine. He currently serves on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics.
Most recently, Dr. Billings was the Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He was also a member of the United States Department of Health and Human Services Secretary's Advisory Committee on Genetics, Health and Society before it was disbanded.
Dr. Billings has had a distinguished career as a physician and researcher. He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine including GeneSage Inc., Omicia Inc., CELLective Dx Corporation and was senior vice president for corporate development at Laboratory Corporation of America Holdings (NYSE; LH). He has held academic appointments at some of the most prestigious universities in the United States including Harvard University, U.C. San Francisco, Stanford University and U.C. Berkeley, and has served as a physician at a number of leading medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008.
Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University. Prior to their recent transactions, Dr. Billings was a Director of Ancestry.com (NASDAQ: ACOM), the Executive Chairman of Signature Genomics Inc., and a Founder of the Cordblood Registry, Inc. He is currently a Board Director of Trovagene Inc. and Collabrx Inc., both publicly traded personalized medicine companies in the United States. He also acts as the Chief Medical Officer of Omicia, Inc. He is a long time Board Member of the Council for Responsible Genetics, the country’s oldest independent biotechnology “watchdog” organization.
Founder and President of United States Diagnostics Standards, Inc.
Jeffrey Cossman, M.D. is the Founder and President of United States Diagnostics Standards, Inc., (USDS) an independent certification body for laboratory and pathology diagnostics. USDS is dedicated to improving the regulatory and commercialization pathways for laboratory diagnostics by verifying the analytical and clinical performance of laboratory diagnostics.
Dr. Cossman is a pathologist and served as Chairman of the Department of Pathology at Georgetown University and as the Oscar B. Hunter Professor of Pathology at Georgetown.
He founded one of the nation’s first Molecular Diagnostics Laboratories while at the National Cancer Institute, where he developed and implemented lymphoma molecular diagnostic tests now in use worldwide. He has also been Vice President and Medical Director of Gene Logic and Chief Science Officer of the Critical Path Institute. Dr. Cossman is a co-founder of Halcyon Diagnostics, Inc., Avalon Pharmaceuticals (now Clinical Data, Inc.), and the Association for Molecular Pathology.
Dr. Cossman has authored 150 scientific publications including the book, Molecular Genetics in Cancer Diagnosis and has several patents in molecular diagnostics. He received his M.D. from the University of Michigan Medical School, is board-certified in pathology and trained in pathology at the University of Michigan, Stanford University and NIH.
President & CEO, Global Liver Institute
Donna R. Cryer, J.D., has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community. Ms. Cryer most recently served as chair, president & chief executive officer of the American Liver Foundation, the largest and oldest national nonprofit organization serving liver disease patients and their families. She was the first patient to lead the organization in its 36-year history.
For eight years, Ms. Cryer has led CryerHealth, a health care consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making.
Her e-health experience includes participating in the launch of the Office of National Coordinator for HIT (ONC) consumer engagement campaign and serving on the ONC technical expert panel on patient-generated health data, participating as a member of the White House e-health equity taskforce and the judging panel on the White House design challenge on innovating the electronic patient medical record. Her blog, DCpatient – An Impatient Patient’s Perspective from Washington, DC, and twitter feed @DCpatient are listed as top resources for insights into emerging e-patients and patient advocates.
Ms. Cryer is a patient representative to the U.S. Food and Drug Administration, a merit reviewer for the Patient Centered Outcomes Research Institute (PCORI), and a member of the Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. Additionally, Ms. Cryer serves on the Gastroenterology Board of the American Board of Internal Medicine, the American Society of Clinical Oncology Guidelines Committee; Hepatitis B Infection Screening in Patients Receiving Chemotherapy for Treatment of Malignant Diseases, the Board of the Personalized Medicine Coalition, is a member of the Patient and Consumer Advisory Council for the Center for Medical Technology Policy, and is an adviser to HarborPath, a patient assistance program for those living with HIV/AIDS and HCV.
Ms. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and received a Juris Doctorate from the Georgetown University Law Center.
She resides in Washington, DC, with her husband, Dennis R. Cryer, MD, FAHA.
Mr. de Crescenzo was appointed President and Chief Executive Officer of Emdeon in September 2013. Prior to that, Mr. de Crescenzo was Senior Vice President and General Manager of Oracle's Global Health Sciences business. Previously, he spent 10 years at IBM Corporation, including his last role as Senior Executive for Global Healthcare Business Consulting Services. Earlier in his career, he held leadership positions in a major hospital system, a large physician practice, and at a major health insurer. Mr. de Crescenzo began his career in investment banking, working with US and European clients in the areas of corporate finance and mergers and acquisitions.
Mr. de Crescenzo earned a B.A. in Political Science from Yale University and an M.B.A. from Northeastern University.
Chief Scientific Officer, Human Longevity, Inc.
Felix Frueh is a respected thought leader in personalized medicine with seventeen years of R&D, management and policy experience. As CSO, Frueh leads all genomic operations including non-clinical microbiome testing, high throughput, next generation genomic sequencing, and research collaborations and partnerships including the program with the University of California, San Diego/Moores Cancer Center. Frueh is also instrumental in guiding HLI’s collaborations and partnerships with the pharmaceutical and diagnostic industry.
Prior to joining HLI Frueh was Executive Partner at Opus Three LLC, a life sciences consulting firm advising pharmaceutical and diagnostic companies on scientific, regulatory, and reimbursement strategies for medical products in the personalized health care space. He was an Entrepreneur-in-Residence at Third Rock Ventures, a Boston-based venture capital firm, where he provided scientific and strategic input for the formation of new and the advancement of existing portfolio companies. Before joining Third Rock, Frueh was President of the Medco Research Institute, leading Medco’s real-world, health economics and outcomes research-oriented initiatives and collaborations after having formed Medco’s personalized medicine research and development organization. Before joining Medco, Frueh was the first Associate Director for Genomics at the U.S. FDA, where he built and led the core genomics review team in CDER, and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG).
Frueh has been a member of various working groups on genetics and genomics at the FDA and Department of Health and Human Services (DHHS). He is the recipient of numerous awards, including the FDA Commissioner’s Special Citation. He serves on the board of the Personalized Medicine Coalition and is also a board member at Enterome Biosciences. Frueh is a Fellow of the American College of Clinical Pharmacology, adjunct faculty member at the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina (UNC) and held faculty appointments in the Departments of Pharmacology and Medicine at Georgetown University in Washington, DC.
Frueh was a postdoctoral fellow at Stanford University and the University of Basel in Switzerland, where he also received his PhD in biochemistry (magna cum laude).
Senior Vice President and Chief Medical Officer, Development Center of Excellence, Eli Lilly & Company
Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director-Duloxetine SUI Team; and European Clinical Research Physician for EVISTA.
Prior to joining Lilly, Dr. Garnett had acquired 7 years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories.
He qualified in Medicine at St. George's Hospital in London. Dr. Garnett is a Fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom. He is also an active board member of the following: Centre for Innovation in Regulatory Science; Indiana Health Industry Forum; and Eiteljorg Museum of American Indians and Western Art.
Board of Trustees Member, American Medical Association
Julie K. Goonewardene is a recognized leader in technology commercialization, business formation, and public/private partnerships. Based on her successes in these areas, Ms. Goonewardene was recently elected to the Board of Trustees for the American Medical Association (AMA).
In addition to serving in her current role as Associate Vice Chancellor for Innovation and Entrepreneurship at the University of Kansas (KU), she is president of KU Innovation & Collaboration and a professor of practice in the KU School of Business. Ms. Goonewardene is responsible for all university-wide commercialization efforts with the intellectual property, company formation, corporate outreach and foundation research relationship groups reporting to her.
Prior to KU, she held various roles at Purdue University. One of her primary focus areas was company formation and capital acquisition for start-up companies. While at Purdue she designed and managed Purdue’s first venture fund. Ms. Goonewardene is an experienced entrepreneur herself, having co-founded and served as president and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired in 2004.
Ms. Goonewardene earned a B.S. degree with Honors in Management and a master’s degree in Health Communication from Purdue University and is currently a member of The Economic Club of Chicago and The Chicago Finance Exchange.
National Medical Director, Oncology Solutions, Aetna
Michael Kolodziej M.D. is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia.
After completing training, Dr. Kolodziej joined the faculty at the University Of Oklahoma School Of Medicine where he was an associate professor.
He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011.In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology.
He has published several manuscripts and given several presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost of care in oncology. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (19) and Katherine (16).
Professor, Department of Pharmaceutics, University of Florida
Lawrence J. Lesko, Ph.D., F.C.P. has been leading UF’s new Center for Pharmacometrics and Systems Pharmacology in the interdisciplinary Institute of Therapeutic Innovation at the UF Research and Academic Center in Lake Nona (Orlando) since July 2011.
Before joining UF, Dr. Lesko worked nearly 20 years in the Food and Drug Administration’s Center for Drug Evaluation and Research as the Director of the Office of Clinical Pharmacology. He was also Chair of the Clinical Pharmacology Coordinating Subcommittee of the FDA’s Medical Policy Coordinating Committee and authored or co-authored numerous Guidance for Industry, and started the FDA’s Voluntary Genomics Data Submission Program and Mechanistic Drug Safety Program.
Dr. Lesko is the recepient of numerous awards related to his expertise in personalized medicine, and has published more than 200 peer-reviewed scientific publications.
Vice President and Head of Pharma Therapeutics Precision Medicine, Pfizer Inc
Aidan Power joined Pfizer in the United Kingdom in 1993 working on the antidepressant, Sertraline, and the antipsychotic, Ziprasidone where he planned, designed and managed multi-national, large-scale Phase III clinical trials. He established a Clinical Pharmacogenetics group in Pfizer in the UK in 1998 and built the framework for the use of genetics in clinical development also establishing the practice of biobanking samples from clinical trials. In 2002, he relocated to Pfizer Global Research and Development Headquarters in New London, Connecticut, and established the Clinical Pharmacogenomics Group. Most recently, as Vice President and Head of PharmaTherapeutics Precision Medicine (formerly Molecular Medicine) at Pfizer, he leads a team that integrates molecular studies across disease areas and develops diagnostics for critical programs in the Pfizer product pipeline.
He is active in a number of groups established to progress pharmacogenomics and personalized medicine and serves on the board of the Serious Adverse Event Consortium (iSAEC) and the Institute of Medicine’s Roundtable on Translating Genomics Based Research for Health.
Dr. Power has a degree in Medicine from University College Cork, Ireland, and trained as a psychiatrist in England. He also obtained a MSc in the History of Science and Medicine at University College London and the Welcome Institute for the History of Medicine.
Vice President for Policy & Research, PhRMA
Lori Reilly is Vice President for Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Ms. Reilly oversees PhRMA’s development of legislative and policy analysis and research studies on health care issues including pharmaceutical economics and utilization, health care quality, direct-to-consumer (DTC) advertising/marketing and promotion, import safety, comparative effectiveness and intellectual property.
In addition to her public policy work, Ms. Reilly is a frequent presenter on industry-related issues and is an industry spokesperson, appearing regularly on CNN, Fox News, ABC News, MSNBC and a host of other media outlets. Ms. Reilly testified before the House Energy and Commerce Subcommittee on Health to discuss the importance of reauthorization of the pediatric exclusivity program and the Food and Drug Administration Globalization Act.
Prior to joining PhRMA, she was counsel at the U.S. House of Representatives Committee on Commerce. And before joining the House Commerce Committee, Ms. Reilly was Chief of Staff to Rep. Jon Christensen.
Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln (1993), where she graduated with Honors, and a J.D. from the University of Nebraska College of Law (1996). She is a Member of the Virginia Bar.
Chief Medical Officer, Leica Biosystems
Jared N. Schwartz, M.D., Ph.D., F.C.A.P., brings 30 years of pathology expertise to his role as Chief Medical Officer at Leica Biosystems. Formerly with Aperio, and previously serving as President of the College of American Pathologists, and Director of Pathology and Laboratory Medicine at Presbyterian Healthcare in Charlotte, North Carolina.
Board certified in anatomic and clinical pathology with subspecialty boards in medical microbiology and cytopathology, he is a graduate of Duke University Medical School, where he completed his residency and fellowship training, and served as chief resident. He was appointed to the Clinical Laboratory Improvement Advisory Committee by HHS, and was a co-chair and author of the ASCO/CAP Guidelines on HER2, which was published in the January 2007 editions of the Journal of Clinical Oncology and Archives of Pathology and Laboratory Medicine and was one of authors of ASCO/CAP Guidelines for ER/PR published in Journal of Clinical Oncology and Archives of Pathology and Laboratory Medicine in 2010. He also serves as a Consulting Professor of Pathology Stanford University.
Senior Vice President, Head of Oncology Clinical Development, Millennium: The Takeda Oncology Company
Michael Vasconcelles, M.D., joined Millennium: The Takeda Oncology Company in 2012 as Senior Vice President, Head of Clinical Development. As part of Millennium's Medical Division Management and Administration, Dr. Vasconcelles has assumed responsibility for the clinical development strategy and execution of the oncology portfolio.
Prior to 2012, Dr. Vasconcelles served as Global Therapeutic Area Head, Transplant and Oncology, at Genzyme. He was responsible for the clinical development and product support of Genzyme's hematologic transplant and oncology portfolio. As a member of the Transplant and Oncology Management team, and Chair of the Transplant and Oncology R&D Council, Dr. Vasconcelles also provided strategic support and oversight to oncology research, business development and commercial strategy for the business. In 2011, following the acquisition of Genzyme by Sanofi, he led the realignment of Genzyme Oncology R&D with Sanofi Global Oncology and was named the Head, Personalized Medicine and Companion Diagnostics.
Before he joined Genzyme, Dr. Vasconcelles was a full time associate physician at Brigham and Women's Hospital and Dana-Farber Cancer Institute. He remains an associate physician at both institutions. He has been on the faculty of the Harvard Medical School since 1996, where he is currently a clinical instructor of medicine.
Dr. Vasconcelles recieved both his B.A. and his M.D. from Northwestern University.
Senior Vice President, Medical, Science and Innovation, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Senior Vice President, Medical, Science and Innovation for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth leads all new test development efforts and is responsible for all science and innovation throughout the company. He also is responsible for Medical Affairs and has a functional reporting responsibility for Medical Quality.
Dr. Wohlgemuth has many years of experience in diagnostics and research and development. Prior to joining Quest Diagnostics in 2009, Dr. Wohlgemuth was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab for Genentech. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. Dr. Wohlgemuth also served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos.
Dr. Wohlgemuth serves as a board member of the Personalized Medicine Coalition, an organization devoted to educating about personalized medicine and promoting new ways of thinking about healthcare. Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.